Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1790-1797

  Benini, Stefania ^a   Manara, Maria Cristina ^a   Baldini, Nicola ^a   Cerisano, Vanessa ^a   Serra, Massimo ^a   Mercuri, Mario ^a,b   Lollini, Pier Luigi ^b   Nanni, Patrizia ^b   Picci, Piero ^a   Scotlandi, Katia ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR; SURAMIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EWING SARCOMA; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BONE NEOPLASMS; BROMODEOXYURIDINE; CELL CYCLE; CELL DIVISION; CELL NUCLEUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; RECEPTOR, IGF TYPE 1; SARCOMA, EWING'S; SURAMIN; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 20244364227     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy
2. Neoadjuvant chemotherapy for Ewing's sarcoma of bone. No benefit observed after adding iphosphamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase. Results of two sequential studies
3. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
4. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma
5. Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients
6. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor
7. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target
8. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor
9. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors
10. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor I receptor
11. Blockade of the type 1 somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
12. cdc2
13. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor receptor mutant
14. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis
15. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion and metastases of breast cancer
16. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice
17. Suramin. A novel antineoplastic agent with multiple potential mechanisms of action
18. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors
19. Antimicrotubule agents
20. Antracyclines and anthracenediones
21. Activation of programmed cell death by anticancer agents: Cisplatin as a model system
22. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
23. Cell-cycle arrest versus cell death in cancer therapy
24. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis
25. Insulin-like growth factor I receptor overexpression mediates cellular resistance and local breast cancer recurrence after lumpectomy and radiation
26. Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblast
27. Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
28. The IGF-I receptor in cell growth, transformation and apoptosis
29. Basis for the acquisition of malignant potential by mouse cells cultivated in vitro